Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer

  • Noriaki Futakawa
  • Wataru Kimura
  • Seiichi Yamagata
  • Bin Zhao
  • Han Ilsoo
  • Tomomi Inoue
  • Naohiro Sata
  • Yoneei Kawaguchi
  • Yoshiro Kubota
  • Tetsuichiro Muto

Abstract:

The early diagnosis of pancreatic carcinoma is essential for increasing patient survival rates. In this study, 52 patients with suspected pancreatic diseases were examined to investigate the value of K-ras codon 12 point mutation, levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19-9), and cytology of pancreatic juice in the diagnosis of pancreatic carcinoma. Pancreatic juice was taken without secretin stimulation. K-ras mutation was detected by enriched polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP). K-ras mutation in pancreatic juice was more frequent in carcinoma than in benign diseases (P = 0.0448). The positive predictive value of K-ras mutation for the diagnosis of neoplastic disease was 83%. The CEA level in pancreatic juice in carcinoma was significantly greater than that in benign disease (P < 0.0001). When the cutoff level of CEA was set at 50 ng/ml, its accuracy for the diagnosis of carcinoma was 85%. A multivariate analysis showed that K-ras mutation and CEA level in pancreatic juice, as well as serum CA19-9 level and age of the patient were independent variables for the diagnosis of carcinoma, and the accuracy of diagnosis by this analysis was increased to 90%. In conclusion, both K-ras mutation and CEA level in pancreatic juice may be valuable for the diagnosis of carcinoma. Better discrimination was possible with a multivariate analysis.

Key words: K-ras, CEA, pancreatic juice, carcinoma of the pancreas, multivariate analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Tokyo 2000

Authors and Affiliations

  • Noriaki Futakawa
    • 1
  • Wataru Kimura
    • 1
  • Seiichi Yamagata
    • 1
  • Bin Zhao
    • 1
  • Han Ilsoo
    • 1
  • Tomomi Inoue
    • 1
  • Naohiro Sata
    • 2
  • Yoneei Kawaguchi
    • 2
  • Yoshiro Kubota
    • 2
  • Tetsuichiro Muto
    • 1
  1. 1.Department of Surgical Oncology, Faculty of Medicine, University of Tokyo, Tokyo, JapanJP
  2. 2.Department of Surgery, Kikkoman General Hospital, Chiba, JapanJP

Personalised recommendations